Marked cardiomegaly in a patient with familial amyloidotic polyneuropathy after orthotopic liver transplantation: a case study. (28th May 2013)

• Record Type: Journal Article
• Authors: Sakashita, Naomi; Kagawa, Seiko; Date, Risako; Ueno, Tatsuro; Nakagawa, Takenobu; Yamashita, Taro; Obayashi, Konen; Ohshima, Toshinori; Ueda, Mitsuharu; Horiguchi, Hidehisa; Ando, Yukio; Takeya, Motohiro
• Is Part Of: Pathology international. Volume 63:Number 5(2013:May)
• Page Start: 260
• Page End: 265
• Publication Date: 2013-05-28
• Subjects: Pathology -- Periodicals; 616.07
• DOI: 10.1111/pin.12055
• Languages: English
• ISSNs: 1320-5463

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Hepatocyte‐derived mutant amyloidogenic transthyretin (ATTR) causes familial amyloidotic polyneuropathy (FAP), for which orthotopic liver transplantation is an established curative treatment. However, some patients with FAP have cardiac amyloidosis after transplantation. Here, we describe a man with an autonomic disorder diagnosed as FAP ATTR Val30Met and marked cardiomegaly after liver transplantation. He underwent orthotopic liver transplantation at 49 years of age and was prescribed prednisolone to prevent graft rejection. Two years later, autonomic dysfunction and severe heart failure gradually developed. He died suddenly at 59. The autopsy revealed marked cardiomegaly (heart weight: 1020 g). Histological and ultrastructural examinations demonstrated massive amyloid deposition and unusual myocardial hypertrophic injury associated with nuclear translocation of the glucocorticoid receptor (GR). No other FAP patients without heart failure showed GR nuclear translocation. GR is a nuclear transcription factor that leads to myocardial hypertrophy, and cumulative prednisolone doses may promote marked cardiomegaly and severe cardiac amyloidosis.</p> </abstract>